Wells Fargo & Company Nuvalent, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NUVL
# of Institutions
188Shares Held
57.1MCall Options Held
500KPut Options Held
179K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.82 Billion31.83% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.57MShares$416 Million14.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$376 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$275 Million0.01% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$245 Million41.86% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.91B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...